Strong growth in emerging markets and Japan, and in consumer healthcare products, offset declines in US pharmaceuticals, GlaxoSmithKline said on Wednesday, as the UK-based drugs group expects strong sales of flu vaccine in the coming months.

“The dynamics of GSK’s business are changing,” said Andrew Witty, chief executive.